Supports rapid implementation of clinical trials targeting multiple sclerosis treatment or management. Funding is available for small-scale proof-of-principle trials and larger phase 1 or 2 trials evaluating safety or efficacy of drugs, biologics, devices, or emerging approaches. Applicants must provide preliminary data and address specific FY26 MSRP CTA focus areas.
Open to any type of entity without restrictions, subject to additional clarifications if provided. Eligible applicants include academic, nonprofit, government, and other organizations.
